{"id":57068,"date":"2026-02-13T13:10:34","date_gmt":"2026-02-13T05:10:34","guid":{"rendered":"https:\/\/flcube.com\/?p=57068"},"modified":"2026-02-13T13:10:35","modified_gmt":"2026-02-13T05:10:35","slug":"salubris-pharma-files-hong-kong-ipo-for-secondary-listing-to-expand-cardiorenal-metabolic-franchise","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57068","title":{"rendered":"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise"},"content":{"rendered":"\n<p><strong>Shenzhen Salubris Pharmaceuticals Co., Ltd.<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/002294:SHE\">SHE:\u202f002294<\/a><\/strong>), a <strong>pioneer in cardiorenal metabolic syndrome treatment in China<\/strong>, has <strong>submitted its IPO prospectus<\/strong> to the <strong>Hong Kong Stock Exchange<\/strong>, pursuing a <strong>secondary listing<\/strong> to <strong>accelerate innovative drug commercialization<\/strong> and <strong>expand global investor access<\/strong>. The company has <strong>transformed from generics to innovation<\/strong>, with <strong>six approved innovative drugs<\/strong> driving <strong>51.6% of pharmaceutical sales<\/strong> in <strong>9M\u202f2025<\/strong>\u2014up from <strong>35.5%<\/strong> in the prior year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:\u202f002294)<\/td><\/tr><tr><td><strong>Current Listing<\/strong><\/td><td>Shenzhen Stock Exchange (A-shares)<\/td><\/tr><tr><td><strong>Target Listing<\/strong><\/td><td>Hong Kong Stock Exchange (H-shares, secondary)<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>Week of 09\u202fFeb\u202f2026<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Cardiorenal metabolic syndrome (hypertension, heart failure, diabetes, CKD)<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Innovation-driven growth; international capital markets access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-innovative-drug-portfolio\">Innovative Drug Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Active Ingredient(s)<\/th><th>Approval<\/th><th>Indication\/Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Allisartan<\/strong><\/td><td>Allisartan<\/td><td><strong>2013<\/strong><\/td><td><strong>First-in-class<\/strong> ARB; hypertension foundation<\/td><\/tr><tr><td><strong>Fulitan<\/strong><\/td><td>Allisartan + Amlodipine<\/td><td><strong>2024<\/strong><\/td><td><strong>Fixed-dose combination<\/strong>; enhanced efficacy and compliance<\/td><\/tr><tr><td><strong>Xinliting<\/strong><\/td><td>Fotagliptin<\/td><td><strong>2024<\/strong><\/td><td><strong>DPP-4 inhibitor<\/strong>; diabetes portfolio expansion<\/td><\/tr><tr><td><strong>Xinchaotuo<\/strong><\/td><td>Sacubitril + Allisartan<\/td><td><strong>2025<\/strong><\/td><td><strong>ARNI + ARB combination<\/strong>; heart failure and hypertension<\/td><\/tr><tr><td><strong>Fulian<\/strong><\/td><td>Allisartan + Indapamide<\/td><td><strong>2025<\/strong><\/td><td><strong>Dual mechanism<\/strong> hypertension control<\/td><\/tr><tr><td><strong>Enneiluo<\/strong><\/td><td>Enarodustat<\/td><td><strong>2023 (initial); 2025 (expansion)<\/strong><\/td><td><strong>HIF-PH inhibitor<\/strong>; anemia in CKD<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-transformation-innovation-revenue-growth\">Financial Transformation: Innovation Revenue Growth<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Period<\/th><th>Innovative Drug Sales % of Total Pharma Revenue<\/th><th>Trend Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>FY\u202f2023<\/strong><\/td><td><strong>30.1%<\/strong><\/td><td>Base year; generics still dominant<\/td><\/tr><tr><td><strong>FY\u202f2024<\/strong><\/td><td><strong>37.7%<\/strong><\/td><td><strong>+7.6 percentage points<\/strong>; innovation acceleration<\/td><\/tr><tr><td><strong>9M\u202f2024<\/strong><\/td><td><strong>35.5%<\/strong><\/td><td>Quarterly fluctuation<\/td><\/tr><tr><td><strong>9M\u202f2025<\/strong><\/td><td><strong>51.6%<\/strong><\/td><td><strong>+16.1 percentage points<\/strong>; <strong>innovation majority achieved<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Inflection:<\/strong> <strong>>50% innovative revenue<\/strong> in <strong>9M\u202f2025<\/strong> validates <strong>R&amp;D investment thesis<\/strong> and <strong>positions for premium valuation<\/strong> in <strong>Hong Kong listing<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-positioning\">Market Context &amp; Competitive Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Cardiorenal Metabolic Market<\/strong><\/td><td><strong>&gt;300 million patients<\/strong> in China with <strong>hypertension, diabetes, heart failure, CKD<\/strong>; <strong>high comorbidity<\/strong> drives <strong>combination therapy demand<\/strong><\/td><\/tr><tr><td><strong>Allisartan Franchise<\/strong><\/td><td><strong>Proprietary ARB platform<\/strong> enables <strong>multiple fixed-dose combinations<\/strong> (Fulitan, Xinchaotuo, Fulian); <strong>differentiation from generic losartan\/valsartan<\/strong><\/td><\/tr><tr><td><strong>Innovation vs. Generics<\/strong><\/td><td><strong>51.6% innovative revenue<\/strong> surpasses <strong>most domestic Chinese pharma<\/strong>; <strong>NRDL pricing power<\/strong> and <strong>market exclusivity<\/strong> vs. <strong>volume-based procurement pressure on generics<\/strong><\/td><\/tr><tr><td><strong>Hong Kong Listing Rationale<\/strong><\/td><td><strong>Dual listing premium<\/strong>; <strong>international institutional investor access<\/strong>; <strong>currency diversification<\/strong>; <strong>M&amp;A currency for global expansion<\/strong><\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td><strong>AZ Fosinopril<\/strong>, <strong>Novo Nordisk diabetes franchise<\/strong>, <strong>Bayer Xarelto<\/strong>; Salubris <strong>domestic innovation positioning<\/strong> captures <strong>policy support<\/strong> and <strong>physician preference<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-use-of-proceeds-amp-growth-strategy\">Use of Proceeds &amp; Growth Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Priority<\/th><th>Application<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>R&amp;D Expansion<\/strong><\/td><td>Next-generation cardiorenal metabolic drugs; siRNA, gene therapy exploration<\/td><td>2026-2028<\/td><\/tr><tr><td><strong>Commercialization Scale<\/strong><\/td><td>Hospital formulary expansion; retail pharmacy channel; digital patient engagement<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>International Expansion<\/strong><\/td><td>Southeast Asia regulatory filings; potential US\/EU partnerships<\/td><td>2027+<\/td><\/tr><tr><td><strong>Manufacturing Upgrade<\/strong><\/td><td>GMP facility modernization; continuous manufacturing implementation<\/td><td>2026-2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Salubris Pharmaceuticals&#8217; Hong Kong IPO completion, innovation revenue growth sustainability, and cardiorenal metabolic market share expansion. Actual results may differ due to HKEX approval timelines, NRDL pricing negotiations, and competitive dynamics with multinational cardiovascular franchises.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26021201240_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26021201240_c.\"><\/object><a id=\"wp-block-file--media-f78606c4-5610-4985-9de4-d850a1547099\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26021201240_c.pdf\">sehk26021201240_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/sehk26021201240_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f78606c4-5610-4985-9de4-d850a1547099\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:\u202f002294), a pioneer in cardiorenal metabolic syndrome treatment in China,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,335,1167],"class_list":["post-57068","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-salubris-pharmaceuticals","tag-she-002294"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:\u202f002294), a pioneer in cardiorenal metabolic syndrome treatment in China, has submitted its IPO prospectus to the Hong Kong Stock Exchange, pursuing a secondary listing to accelerate innovative drug commercialization and expand global investor access. The company has transformed from generics to innovation, with six approved innovative drugs driving 51.6% of pharmaceutical sales in 9M\u202f2025\u2014up from 35.5% in the prior year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57068\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise\" \/>\n<meta property=\"og:description\" content=\"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:\u202f002294), a pioneer in cardiorenal metabolic syndrome treatment in China, has submitted its IPO prospectus to the Hong Kong Stock Exchange, pursuing a secondary listing to accelerate innovative drug commercialization and expand global investor access. The company has transformed from generics to innovation, with six approved innovative drugs driving 51.6% of pharmaceutical sales in 9M\u202f2025\u2014up from 35.5% in the prior year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57068\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T05:10:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-13T05:10:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1304.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57068#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57068\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise\",\"datePublished\":\"2026-02-13T05:10:34+00:00\",\"dateModified\":\"2026-02-13T05:10:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57068\"},\"wordCount\":454,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57068#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1304.webp\",\"keywords\":[\"IPO\",\"Salubris Pharmaceuticals\",\"SHE: 002294\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57068#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57068\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57068\",\"name\":\"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57068#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57068#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1304.webp\",\"datePublished\":\"2026-02-13T05:10:34+00:00\",\"dateModified\":\"2026-02-13T05:10:35+00:00\",\"description\":\"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:\u202f002294), a pioneer in cardiorenal metabolic syndrome treatment in China, has submitted its IPO prospectus to the Hong Kong Stock Exchange, pursuing a secondary listing to accelerate innovative drug commercialization and expand global investor access. The company has transformed from generics to innovation, with six approved innovative drugs driving 51.6% of pharmaceutical sales in 9M\u202f2025\u2014up from 35.5% in the prior year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57068#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57068\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57068#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1304.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1304.webp\",\"width\":1080,\"height\":608,\"caption\":\"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57068#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise - Insight, China&#039;s Pharmaceutical Industry","description":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:\u202f002294), a pioneer in cardiorenal metabolic syndrome treatment in China, has submitted its IPO prospectus to the Hong Kong Stock Exchange, pursuing a secondary listing to accelerate innovative drug commercialization and expand global investor access. The company has transformed from generics to innovation, with six approved innovative drugs driving 51.6% of pharmaceutical sales in 9M\u202f2025\u2014up from 35.5% in the prior year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57068","og_locale":"en_US","og_type":"article","og_title":"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise","og_description":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:\u202f002294), a pioneer in cardiorenal metabolic syndrome treatment in China, has submitted its IPO prospectus to the Hong Kong Stock Exchange, pursuing a secondary listing to accelerate innovative drug commercialization and expand global investor access. The company has transformed from generics to innovation, with six approved innovative drugs driving 51.6% of pharmaceutical sales in 9M\u202f2025\u2014up from 35.5% in the prior year.","og_url":"https:\/\/flcube.com\/?p=57068","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-13T05:10:34+00:00","article_modified_time":"2026-02-13T05:10:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1304.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57068#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57068"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise","datePublished":"2026-02-13T05:10:34+00:00","dateModified":"2026-02-13T05:10:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57068"},"wordCount":454,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57068#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1304.webp","keywords":["IPO","Salubris Pharmaceuticals","SHE: 002294"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57068#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57068","url":"https:\/\/flcube.com\/?p=57068","name":"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57068#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57068#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1304.webp","datePublished":"2026-02-13T05:10:34+00:00","dateModified":"2026-02-13T05:10:35+00:00","description":"Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:\u202f002294), a pioneer in cardiorenal metabolic syndrome treatment in China, has submitted its IPO prospectus to the Hong Kong Stock Exchange, pursuing a secondary listing to accelerate innovative drug commercialization and expand global investor access. The company has transformed from generics to innovation, with six approved innovative drugs driving 51.6% of pharmaceutical sales in 9M\u202f2025\u2014up from 35.5% in the prior year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57068#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57068"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57068#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1304.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1304.webp","width":1080,"height":608,"caption":"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57068#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1304.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57068"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57068\/revisions"}],"predecessor-version":[{"id":57073,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57068\/revisions\/57073"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57072"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}